Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
27 juin 2024 02h30 HE
|
Bioxodes
Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
27 juin 2024 02h30 HE
|
Bioxodes
First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
[Latest] Global Gym Equipment Market Size/Share Worth USD 27,420.9 Million by 2033 at a 4.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
19 juin 2024 04h30 HE
|
Custom Market Insights
Austin, TX, USA, June 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Gym Equipment Market Size, Trends and Insights By Product Type (Cardiovascular...
New Findings Revealed on Kyolic Aged Garlic Extract Research at 7th Annual International Garlic Symposium
05 juin 2024 10h00 HE
|
Wakunaga of America
MUNICH, June 05, 2024 (GLOBE NEWSWIRE) -- The latest research on Wakunaga of America’s Aged Garlic Extract (AGE) was presented at the 7th International Garlic Symposium: Frontiers of Garlic Research...
L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et...
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases,...
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
14 mai 2024 15h19 HE
|
Meacor inc.
MEACOR Secures $15 Million in Series A Funding to Advance Innovative Transcatheter Heart Valve Repair Technology
[Latest] Global mHealth Market Size/Share Worth USD 374.6 Billion by 2032 at a 17.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
14 mars 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, March 14, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “mHealth Market Size, Trends and Insights By Device Type (Cardiac Monitors,...
Medical Biomimetics Market Size is projected to reach USD 54.25 billion by 2031, growing at a CAGR of 6.5%: Straits Research
14 mars 2024 09h20 HE
|
Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- Medical biomimetics, also known as biomimicry or bioinspired technology, is a field that creates and develops novel medical treatments,...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
07 mars 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...